Sanofi Genzyme Competitors and Similar CompaniesClear all

Sanofi Genzyme's competitors and similar companies include Biogen, Amgen, Amicus Therapeutics and Aqemia.
Sanofi Genzyme
Sanofi Genzyme
Sanofi Genzyme (also known as Genzyme Corporation) is a biotech company that specializes in rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology.
Biogen
Biogen
Biogen is a biotechnology company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.
Amgen
Amgen
Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Aqemia
Aqemia
Aqemia is a company that develops molecule matching technology.
Founding Date
Founding Date
1981
Founding Date
1978
Founding Date
1980
Founding Date
2002
Founding Date
2019
Type
Type
Subsidiary
Type
Public
Type
Public
Type
Public
Type
Private
Tags
Locations
Locations
Cambridge, US HQ
Macquarie Park, AU
Malaga, AU
Virginia, AU
São Paulo, BR
Mississauga, CA
Toronto, CA
see more
Locations
Cambridge, US HQ
Vicente López, AR
Macquarie Park, AU
Wien, AT
Machelen, BE
São Paul, BR
Toronto, CA
see more
Locations
Thousand Oaks, US HQ
Hydra, DZ
Vicente López, AR
Sydney, AU
Wien, AT
Diegem, BE
Santo Amaro, BR
see more
Locations
Philadelphia, US HQ
Northbridge, AU
Pointe Claire, CA
Paris, FR
München, DE
Dublin, IE
Milano, IT
see more
Locations
Paris, FR HQ
Paris, FR
Employees
Employees
9,9041% decrease
Employees
9,6106% increase
Employees
25,200
Employees
58415% increase
Employees
5612% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
32.1 b
Valuation ($)
150.2 b
Valuation ($)
3.8 b
Valuation ($)
N/A
Twitter followers
Twitter followers
59.6 k
Twitter followers
45.7 k
Twitter followers
123.5 k
Twitter followers
2.1 k
Twitter followers
N/A
Number of tweets (last 30 days)
Number of tweets (last 30 days)
2
Number of tweets (last 30 days)
20
Number of tweets (last 30 days)
91
Number of tweets (last 30 days)
10
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
4.5
Average likes per tweet (last 30 days)
4.6
Average likes per tweet (last 30 days)
4.8
Average likes per tweet (last 30 days)
2.2
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
95%
Percentage of tweets with engagement (last 30 days)
97.8%
Percentage of tweets with engagement (last 30 days)
80%
Percentage of tweets with engagement (last 30 days)
N/A
Employee Rating
Employee Rating
N/A
Employee Rating
4
Employee Rating
4.1
Employee Rating
2.9
Employee Rating
N/A

Financial

Revenue (est.)
Revenue (est.)
€10.4b (FY, 2019)
Revenue (est.)
$9.8b (FY, 2023)
Revenue (est.)
$28.2b (FY, 2023)
Revenue (est.)
$399.4m (FY, 2023)
Revenue (est.)
N/A
Cost of goods
Cost of goods
N/A
Cost of goods
$2.5b (FY, 2023)
Cost of goods
$8.5b (FY, 2023)
Cost of goods
$37.3m (FY, 2023)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$7.3b (FY, 2023)
Gross profit
$19.7b (FY, 2023)
Gross profit
$362m (FY, 2023)
Gross profit
N/A
Net income
Net income
N/A
Net income
$1.2b (FY, 2023)
Net income
$6.7b (FY, 2023)
Net income
($151.6m) (FY, 2023)
Net income
N/A

Operating

Countries
Countries
100 (Nov, 2020)
Countries
N/A
Countries
100 (FY, 2020)
Countries
N/A
Countries
N/A
Patents (US)
Patents (US)
605 (Nov, 2020)
Patents (US)
21 (FY, 2021)
Patents (US)
31 (FY, 2020)
Patents (US)
N/A
Patents (US)
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
10 (Q2, 2022)
Phase I Trials Products
20 (FY, 2020)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
8 (Q2, 2022)
Phase II Trials Products
5 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
9 (Q2, 2022)
Phase III Trials Products
11 (FY, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 88m
Total funding raised
$ 1.1m
For sources of this data, please see the company profile

View Company Profiles

Biogen
HQ
Cambridge, US
Employees
9,610↑ 6% increase

Biogen is a biotechnology company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.

View company
Amgen
HQ
Thousand Oaks, US
Employees
25,200

Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.

View company
Amicus Therapeutics
HQ
Philadelphia, US
Employees
584↑ 15% increase

Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.

View company
Aqemia
HQ
Paris, FR
Employees
56↑ 12% increase

Aqemia is a company that develops molecule matching technology.

View company